Introduction: Urologic chronic pelvic pain syndrome (UCPPS), which includes interstitial cystitis/bladder pain syndrome and chronic prostatitis, is associated with increased voiding frequency, nocturia, and chronic pelvic pain. Current treatment options have limited efficacy and are often associated with detrimental side effects. New targets and signaling mechanisms must be explored to understand the symptomology of this disease and develop more efficacious treatments. Interestingly, while tissue changes in human and animal models Therefore, we aim to test the hypotheses that UCPPS patients have dysregulated angiotensin signaling, resulting in increased hypertension compared to controls. Secondly, we aimed to evaluate symptom severity in patients with and without hypertension and with and without antihypertensive medication use. Methods: Data from UCPPS patients (n=424), fibromyalgia (positive controls, n=200), and healthy controls (n=415) were obtained from the NIDDK Multi-Disciplinary Approach to the Study of Chronic Pelvic Pain I (MAPP). Diagnosis of hypertension, current hypertensive medications, pain severity, and urinary symptom severity were analyzed using chi-square test and t-test. Results: UCPP patients had a greater incidence of hypertension (23% vs 17% vs 12% respectively, p < 0.001) and reported more overall hypertensive drug use compared to controls (23% vs 17% vs 16%, p<0.001). Patients (n=7) with a hypertension diagnosis not on hypertensive medications reported the greater severity of pain and urinary symptoms. Conclusion: Further investigation on the relationship between hypertension, hypertensive drug use, and UCPP and the role of angiotensin signaling in UCPP conditions is needed